PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Peptides. Author manuscript; available in PMC 2010 October 1.
Published in final edited form as:
PMCID: PMC2755606
NIHMSID: NIHMS136146

Central leptin gene therapy ameliorates diabetes type 1 and 2 through two independent hypothalamic relays

a benefit beyond weight and appetite regulation

Abstract

Although its role in energy homeostasis is firmly established, the evidence accumulated over a decade linking the adipocyte leptin -hypothalamus axis in the pathogenesis of diabetes mellitus has received little attention in the contemporary thinking. In this context various lines of evidence are collated here to show that (1) under the direction of leptin two independent relays emanating from the hypothalamus restrain insulin secretion from the pancreas and mobilize peripheral organs - liver, skeletal muscle and brown adipose tissue - to upregulate glucose disposal, and (2), leptin insufficiency in the hypothalamus produced by either leptinopenia or restriction of leptin transport across the blood brain barrier due to hyperleptinemia of obesity and aging, initiate antecedent pathophysiological sequalae of diabetes type 1 and 2. Further, we document here the efficacy of leptin replenishment in vivo, especially by supplying it to the hypothalamus with the aid of gene therapy, in preventing the antecedent pathophysiological sequalae-hyperinsulinemia, insulin resistance and hyperglycemia - in various animal models and clinical paradigms of diabetes type 1 and 2 with or without attendant obesity. Overall, the new insights on the long-lasting antidiabetic potential of two independent hypothalamic relays engendered by central leptin gene therapy and the preclinical safety indicators in rodents warrant further validation in subhuman primates and humans.

Keywords: Leptin gene therapy, Hypothalamus, Diabetes mellitus type 1 and 2

1. INTRODUCTION

Insulin produced by pancreactic β-cells facilitates glucose homeostasis by promoting glucose uptake and storage in skeletal muscle, liver and fat cells. Either lack or inefficient use of insulin by these peripheral targets coalesces into diabetes, a chronic disease characterized by hyperglycemia which over time may inflict a spectrum of metabolic and neural diseases and shorten life-span [33,34,53,55,67,72]. Diabetics suffer from either type 1 or type 2 diabetes. Type 1 diabetes is a debilitating autoimmune disease caused by T-cell mediated gradual destruction of β-cells, leading to either insufficient or complete lack of insulin production [17,29,33,34,72,82]. Insulin replacement regimens aimed at reproducing the physiological range of blood glucose levels are the treatment of choice for these patients [72,82]. Type 2 diabetes is a progressive chronic disease that can manifest at any age due largely to persistent metabolic imbalance engendered by myriads of internal and external environmental factors, including diet and lifestyle changes [17,29,33,34,72,82]. Increases in episodic basal and post-prandial insulin secretion initiated by these environmental shifts gradually lead to insulin receptor insensitivity, insulin resistance and diminished downstream insulin receptor signaling in target cells. The relentless compensatory insulin hypersecretion to normalize blood glucose levels under these conditions expedites β-cell dysfunction and loss that eventuates into unremitting hyperglycemia[9,33,35,53,55,70,71]. The onset of these pathophysiological sequalae of type 2 diabetes is highly correlated with increasing adiposity and age [29,33-35,53,55,60,79,80]. Interventional therapies that delay or prevent entirely the inevitable adverse health consequences of type 2 diabetes include insulin administration and injectable and orally effective antidiabetic drugs [33,63,72,82]. However, current therapies for these two etiologically distinct diseases are cumbersome, as they require daily administration or continuous infusion of insulin and antidiabetic drugs, along with constant monitoring by patients and physicians for glycemic control, all of which, in aggregate, substantially escalate medical costs [29,33,53,55,63,72,79,80,82].

Historically, ever since the recognition of insulin as the indispensable signal molecule in maintaining glucose homeostasis, research has been devoted entirely to deciphering the external and internal environmental factors at the systemic, cellular and molecular levels that regulate insulin secretion and endogenous pathways that integrate glucose disposal for tight glycemic control [6,33,55,72,82]. This expanding knowledge has continued to singularly steer research towards improving ways to optimally deliver insulin and identify newer insulin mimetics. The possibility that there may exist additional endogenous signal molecules and alternate peripheral and central pathways, that either on their own or in concert with insulin orchestrate homeostatic cues for tight glycemic control, and may, thus, offer novel therapeutic avenues, has received little attention in contemporary thinking (Fig. 1) [33,34,56,72,82].

Figure 1
Peripheral and central sequence of events mediating the obesity-induced type 2 diabetes. For details see text. CNS, central nervous system; OB-Ra, short isoform of leptin receptor; OB-Rb, long isoform of leptin receptor. Adapted with permission from ref. ...

Indeed, it has been known for a long time that neural signals from the brain, especially those emanating from the hypothalamus, are quite important in the dynamic operation of the insulin-glucose axis [12,27,37,38,40]. Ablation of either the ventromedial nucleus (VMN) or the paraventricular nucleus of the hypothalamus in rodents accelerated insulin secretion not only prior to the onset of hyperphagia and increased rate of fat accretion but blood insulin levels remained elevated in concert with progression towards morbid obesity [12,27,37,38,40]. These rapid and pronounced permanent shifts in the insulin-glucose axis have long been assumed as a secondary manifestation in response to unregulated ingestive behavior and adiposity. The identification of leptin, primarily produced by white adipose tissue (WAT), as a major hormonal signal in the hypothalamic integration of energy homeostasis [20,35,37,38,55,68,93], and subsequent unraveling of additional multiple regulatory effects of leptin exerted through the hypothalamus on various physiological systems, re-established a pivotal role of afferent neural relays in the bidirectional communication between the periphery and brain [13,17,21,29,32,35,40,47,55,58-60,78,85].

Consequently, apart from a mandatory regulatory role in energy intake and expenditure [10,35,38,40,93], independent participation of leptin in the hypothalamic integration of insulin-glucose homeostasis and the new understanding that a breakdown in the cross-talk between WAT and hypothalamus is, indeed, an etiologic factor in the pathogenesis of diabetes is collated in this review. Also, within this context are detailed, (i) hypothalamic relays that influence insulin secretion and glucose disposal under the direction of leptin, (ii) a critical role of antecedent leptin insufficiency in the hypothalamus in causation of pathophysiological sequalae of diabetes type 1 and 2, and (iii) interventions that reinstate central leptin sufficiency to lessen or eliminate the shortcomings of current therapies.

2. LEPTIN RESTRAINT ON INSULIN SECRETION PRIMARILY THROUGH HYPOTHALAMIC RELAYS

That leptin exerts a dynamic regulatory restraint on insulin secretion is suggested by numerous clinical and animal studies [2,22-24,28,35,66,68-70,74]. Insulin is adipogenic, promotes leptin secretion and fat deposition in the body (Figs. (Figs.11,,2)2) [29,33,35,36,47,55]. Since leptin can inhibit insulin efflux from β-cells, a peripheral adipo-insular feedback loop was suggested to tightly regulate leptin and insulin secretion (Fig. 1) [33,47]. On the other hand, subsequent in vivo evidence revealed an alternative route that leptin-responsive central, and not peripheral mechanisms, exert a restraint on insulin secretion from β-cells (Fig. 1) [1,2,8,9,20,23-25,31,35,36,46,50,68,70,71,83,90]. The evidence that interruption of leptin-induced neural relays by either lesioning the VMN or surgical transection of descending hypothalamic tracts or deletion of leptin receptors in hypothalamic neurons lets on insulin hypersecretion preceding an increase in fat accretion and morbid obesity [20,27,35,39,46,75], and intraventricular infusion of leptin suppressed blood insulin levels and increased receptor sensitivity prior to any discernable decrease in weight and adiposity endorses the involvement of central leptin receptors [31,41,56,61,76]. The possibility that centrally infused leptin in these paradigms may have leaked into the peripheral circulation in amounts sufficient to restrain insulin secretion directly from β-cells, was ruled out by the observation that when leptin expression was increased locally in the hypothalamus, without leakage to the periphery it exerted a stable and pronounced suppression of blood insulin levels [1,2,9,10,23,25,36,54].

Figure 2
Schematic depiction of the role of leptin sufficiency (A) and insufficiency (B) in the hypothalamus in sustaining normoglycemia and diabetes, respectively. A. Leptin sufficiency in the hypothalamus is maintained by an active process of leptin transport ...

Additionally, it is now amply evident that sufficiency in afferent leptin signaling to the hypothalamus is critical in the regulatory restraint on insulin secretion [35]. Despite existent hyperleptinemia, leptin concentrations in the hypothalamus were consistently found to be significantly lower in obese patients and rodents than those in non-obese counterparts [3-5,15,16,43-45,52,73]. Attenuation of leptin entry across the blood brain barrier (BBB) by an active leptin receptor mediated process by hyperleptinemia was shown to decrease brain leptin levels [43-45]. Further, a gradual transition to leptin insufficiency in the hypothalamus, temporally associated with increases in blood leptin levels, was coincident with the rise in blood insulin levels and fat accrual [3-5,7,10,23,24,70,71]. The evidence that leptin replacement centrally abolished hyperinsulinemia in obese rodents corroborated the formulation that it is leptin insufficiency that normally favors insulin hypersecretion by relieving the restraint on β-cells, a response necessary for enhancing the conversion of excess energy into fat [33,35,40,55,87]. Similarly, hyperinsulinemia was abolished when leptin signaling was reinstated by installation of leptin receptors in discrete hypothalamic sites in leptin receptor mutants [46]. Also, findings from congenital lipodystrophic patients and transgenic mice invoke central leptin insufficiency as a contributor in the genesis of hyperinsulinemia [28,66,69,74,77]. Hyperinsulinemia and diabetes type 2 concomitant with severe leptinopenia in these subjects was completely abrogated by leptin replacement without affecting food intake and weight. Because an intact VMN is necessary for hyperleptinemia to suppress hyperinsulinemia, one can safely conclude that central leptin insufficiency created by leptinopenia in congenital lipodystrophic patients and mice was overcome by increased leptin availability for entry across the BBB to reinstate leptin restraint and suppress hyperinsulinemia by activating descending hypothalamic relays and not by directly inhibiting insulin hypersecretion from β-cells (Figs. (Figs.11,,2)2) [35,38,39,50,90].

Thus, taken together with the recent disclosure of distinct neural pathways linking the hypothalamus to the pancreas [14,51], involving the local network of neuropeptide Y and cohorts (Figs. (Figs.11,,2)2) [7,40,57], this large body of experimental evidence is consistent with the view that a dynamic cross-talk between adipocytes and hypothalamus is mandatory in maintaining tonic restraint on insulin efflux from β-cells [9,35].

3. UPREGULATION OF GLUCOSE METABOLISM BY LEPTIN THROUGH HYPOTHALAMIC RELAYS, INDEPENDENT OF INSULIN INVOLVEMENT

Leptin is also a significant player in the regulation of glucose metabolism. Systemic administration of leptin to either leptin-deficient ob/ob [19,35,41,61,89] or leptinopenic lipodystrophic, diabetic humans and mice stimulated glucose metabolism and normalized blood glucose concentrations, benefits previously attributed to activation of leptin receptors on hepatocytes, islet cells, adipocytes and skeletal muscle cells [19,29,30,33,47,53,55]. However, these very benefits, i.e. glucose lowering and sustenance of euglycemia, were launched when leptin was provided solely in the hypothalamus of not only WT rodents, but also insulinopenic diabetic Akita mice and streptozotocin-treated rodents with insulitis [8,9,23,31,35,39,40,48,49,70,71,83,84]. Increased leptin signaling in the hypothalamus in these paradigms modified glucose metabolism, independent of insulin, by a coordinated orchestration of target genes involved in glucose uptake and utilization in liver, skeletal muscle and brown adipose tissue (BAT) (Fig. 1) [8,9,23,31,35,38,40,48,49,56,84,88,91]. Thus, unlike the previous assumption [29,33,47,53,55,68,80], normoglycemia induced by systemic injections of leptin in these paradigms is likely a consequence of augmented glucose disposal imposed by central receptors after its entry across the BBB to the hypothalamus [35,37,43-45]. Furthermore, despite substantially reduced blood insulin concentrations, sustenance of glucose metabolism in leptin over-expressing transgenic Skinny mice [66], in a manner similar to that evoked by hypothalamic leptin receptor activation in lean insulinopenic Akita mice, also invokes participation of central receptors in maintaining elevated rates of glucose disposal [26,84]. Innervations from the hypothalamus conceivably transmit leptin-induced outflow to upregulate glucose metabolism in pancreas, liver, skeletal muscle, WAT and BAT (Fig. 2) [14,51,86].

In sum, apart from food intake regulation, optimal leptin signaling in the hypothalamus is essential for orchestration of glucose homeostasis through independent controls on insulin secretion and glucose metabolism. Leptin insufficiency in the hypothalamus, produced by either leptinopenia or hyperleptinemia, is apparently a common antecedent causal factor in the pathogenesis of diabetes [4,5,15,16,35,43,69,71,74,84,87]. This insight raises an obvious clinically relevant question: can prevention of central leptin insufficiency decelerate or alleviate the pathogenesis of type 1 and type 2 diabetes?

4. AMELIORATION OF DIABETES BY STABLE LEPTIN SUPPLY

Research in gene transfer strategies to develop interventional therapies for various neural diseases has proceeded at a rapid pace [18,35,36,39,40,42,46]. It is now feasible to introduce genes into cells to replace a missing gene in order to correct or augment the target gene function to cure or slow the progression of chronic diseases due to genetic abnormalities, environmental insults and metabolic imbalance. Gene transfer technology thus offers a potentially newer means to harness an optimal supply of bioactive leptin for overcoming leptin insufficiency for extended periods [11,22,36,39,40,64,65,90]. Among the various viral vectors available for gene transfer, recombinant adenovirus (rADV) and recombinant adeno-associated virus (rAAV) encoding leptin have been employed to delineate the role of leptin in integration of energy homeostasis [18,39,40,42]. Although rADV can infect dividing and non-dividing cells with little integration into the host genome, it transduces high level of transgene expression only transiently and rapidly elicits a robust immune reaction to viral protein, an issue of considerable safety concern [18,39,42,65]. On the other hand, replication-deficient rAAV is non-immunogenic and non-pathogenic, it can infect dividing and non-dividing cells with marked facility, and after integration into the host genome it evokes transgene expression for the lifetime of the cell [18,40,42,64]. Since an ideal anti-diabetic therapy should be safe in establishing relatively rapid and long-lasting glycemic control, without disrupting or only minimally perturbing the homeostatic physiological and neural interactions, the benefits of leptin gene transfer with the aid of either rADV or rAAV on hyperinsulinemia and hyperglycemia, the antecedent pathophysiological sequalae of diabetes associated with or without obesity, are summarized below.

4.1 Diabetes type 2

4.1.1 Insulin hypersecretion

Hyperinsulinemia and insulin resistance, the predisposing conditions for diabetes type 2, manifest either gradually with advancing age or rapidly in response to consumption of energy-enriched diets and sedentary life-style. Increased incidence of diabetes type 2 has been reported to closely correlate with increased weight predominantly due to visceral obesity [24,29,33,35,55,63,80]. Hyperleptinemia produced by a single intravenous or intramuscular injection of either rADV encoding leptin (rADV-lep) or rAAV-lep to either WT rodents or hyperinsulinemic and hyperglycemic obese ob/ob mice, markedly decreased blood insulin and glucose levels along with reduced weight and fat depletion [18,22,50,65], the benefits lasting the duration of experiments, generally for much shorter duration in rADV-lep than in rAAV-lep injected rodents [18,22,50,64,65,92]. However, because of the fact that leptin is pleiotropic, correction of hyperinsulinemia and hyperglycemia by viral vector-induced hyperleptinemia are tempered by health safety concerns. Hyperleptinemia is lipotoxic on adipose and non-adipose tissues, it can adversely impact immune function, bone formation, angiogenesis, the cardiovascular system and renal function [13,21,29,32,36,40,47,55,58-60,78,82]. Moreover, hyperleptinemia enforces BBB impervious to leptin entry [3-5,15,16,43-45,73], and the resultant insufficiency in the hypothalamus, in turn, renders subjects vulnerable to a multitude of neural and non-neural diseases [35].

It is possible to circumvent the deleterious consequences of hyperleptinemia by supplying leptin directly into the hypothalamus to engage neural pathways mediating the control on insulin secretion and glucose metabolism [3,56,61,62,76]. Indeed, a single injection of rAAV-lep either intracerebroventricularly (icv) to augment leptin expression in multiple hypothalamic sites that display biologically relevant long form of leptin receptor [8-10,23-25,37-40], or microinjection into a discrete site to elevate leptin transgene expression locally without spread of leptin to either neighboring sites, cerebrospinal fluid or peripheral circulation, was found just as efficacious as peripheral administration of the vector [1,2,9,11,83,84]. After a single icv rAAV-lep administration to prepubertal rodents, various centrally mediated benefits of leptin persisted throughout the lifetime [9,10] and through various phases of the lifecycle, reproduction, lactation and post-lactation after central injection to adult female rats [54]. Specifically, icv rAAV-lep injection suppressed the age-related and energy enriched high fat diet (HFD)-induced risk factors for diabetes type 2, namely, hyperinsulinemia and insulin resistance, accompanied with or without decreases in weight and adiposity [23-25,70,71,83,84]. This remarkable ability of central leptin transgene expression to repress basal episodic and post-prandial insulin hypersecretion in WT rodents consuming normal rodent chow or HFD was rapid and preceded the changes in weight. A similar diminution of insulin efflux occurred after microinjection of rAAV-lep in discrete hypothalamic sites of rats consuming normal low-calorie rodent chow or HFD [1,2]. To counter a remote possibility that circulating leptin levels, albeit in the low range, participated in lowering insulin levels and enhancing insulin sensitivity, it was shown in subsequent experiments that in the absence of circulating leptin in the ob/ob mice, supply of leptin solely in the hypothalamus clamped insulin hypersecretion and extinguished insulin resistance even when these mice were challenged with calorie-enriched HFD diet that normally evokes symptoms of diabetes [9,83,84].

4.1.2 Hyperglycemia

An unanticipated finding of these investigations was that leptin transgene expression in the hypothalamus resulted in euglycemia in all these varied rodent paradigms, despite a robust contemporaneous clamp on insulin secretion from pancreas [1,2,9,10,23-25,41,62,83,84]. Presumably, the heightened insulin sensitivity that accompanied insulinemia after icv rAAV-lep injection was responsible for the sustained euglycemia [9,83,84]. Intriguingly, an additional player assisting in maintaining this divergent outcome, i.e. insulinemia coexistent with euglycemia, was the rise in BAT-mediated thermogenic energy expenditure and up-regulation of glucose metabolism and disposal [9,83,84]. Seemingly, a stable increase in hypothalamic leptin signaling has the potential to optimize glucose metabolism and impose tight glycemic control, with either minimal assistance, as reflected by the prevailing insulinopenia, or independent of insulin participation, as presented in the following section on diabetes type 1.

Nevertheless, these findings clearly illustrate that central leptin gene therapy can correct the predisposing risks of type 2 diabetes by enforcing distinct neurally mediated two-prong action, repression of hyperinsulinemia by a restraint on insulin efflux from β-cells, and up-regulation of glucose metabolism in the body.

4.2 Diabetes type 1

4.2.1 Hyperglycemia

The unanticipated observation that leptin supply in minute amounts directly to central sites can stably confer euglycemia despite a clamp on insulin efflux from pancreas [1,2,9,10,23-25,83,84], channeled investigations in our laboratory towards addressing a highly pertinent question; can enhanced leptin supply similarly impose euglycemia for extended periods in paradigms of type 1 diabetes? In the first paradigm Akita mice that are severely insulinopenic due to a dominant mutation in Ins 2 gene and suffering from early onset of raging hyperglycemia were employed [60,84]. A single icv injection of rAAV-lep in adult Akita mice abolished hyperglycemia and diabetes mellitus by enhancing the rate of glucose disposal and insulin sensitivity [60,84]. In fact, normoglycemia was imposed within a week after icv rAAV-lep injection and it was sustained for the 7 week duration of the experiment. This euglycemic response was accompanied by increased BAT-mediated thermogenic energy expenditure in a manner similar to that seen in WT and hyperinsulinemic, obese ob/ob mice [9,84]. In the second paradigm, the efficacy of rAAV-lep to impel euglycemia was tested in mice with insulitis produced by an injection of streptozotocin, a research paradigm employed for decades to assess the pathophysiology of type 1 diabetes. STZ-treated rodents suffer from typical symptoms of diabetes mellitus, unremitting hyperglycemia, weight loss despite hyperphagia, and early mortality [48,49]. An icv injection of rAAV-lep shortly after STZ administration, rescued these mice from early mortality, curbed hyperphagia and maintained reduced BW along with sustenance of euglycemia during the entire course of the experiment lasting for one year [48,49]. No behavioral modification or signs of diabetic cardiomyopathy and low grade systemic inflammation were discernible [26,60]. In concordance with these results observed after central rAAV-lep injection, Yu et al. [92] found that elevations in blood levels of leptin several fold above the normal range with the aid of intravenous injection of rADV-lep, first transiently prevented hyperglycemia and then, over time, sustained higher blood glucose concentrations in correlation with decreases in blood leptin, and delayed mortality in STZ-pretreated rats [92]. Similar hyperleptinemia produced by systemic administration of rADV-lep in non-obese diabetic (NOD) mice, a well-established model of diabetes type 1 resulting from an autoimmune disease [72,92], first imposed normoglycemia, but later blood glucose levels rose to a range below that in severely hyperglycemic control NOD mice. Food intake was reduced and BW loss was also minimized in association with hyperleptinemia in these two paradigms of diabetes type 1 for the duration of the experiments. As evidenced by the fact that minute leptin supply solely in the hypothalamus can abrogate hyperglycemia in Akita and STZ-treated mice [48,49,60,84], it is highly likely that attenuation of hyperglycemia by peripheral hyperleptinemiareported by Yu et al. [92] was orchestrated subsequent to leptin entry across the BBB into the hypothalamus.

5. CONCLUDING REMARKS

A striking inference of these investigations is that leptin in the circulation or available centrally alone, can mimic insulin-like glucose lowering effects in the complete absence of insulin. More importantly, the outcome of the central leptin gene transfer studies illuminates a substantive leptin link in the etiology of diabetes (Fig. 2). Since stable leptin supply blocked the dire life-threatening pathophysiological consequences of diabetes, central leptin gene therapy is potentially a reliable substitute for insulin therapy [10,11,34-36,39,40]. It is amply clear that only a minute amount of leptin within hypothalamic targets can optimally repress hyperinsulinemia for as long as the supply lasts (Fig. 1). Seemingly, post-synaptic response to leptin remains unabated and the leptin-induced downstream intracellular signaling which is apparently distinct from that transduced by insulin [33,81,92], is not compromised by the sustained leptin supply at central targets. As to how, even in the absence of insulin, neural signaling transduced by leptin transgene expression in the hypothalamus alone optimizes the rate of glucose metabolism and improves insulin sensitivity to orchestrate a long-lasting euglycemia (Fig. 2), is not fully understood.

Finally, the incidence of diabetes mellitus in young and adult populations is rising at an alarming pace worldwide [17,29,53,55]. The pandemic has ignited new research endeavors aimed at designing remedies based on newer insights on the genesis of pathophysiological sequalae that eventually inflict type 1 and type 2 diabetes. This drive is also catalyzed by the ever rising cost of treating multiple co-morbidities of diabetes including hypertension, cardiovascular ailments, nervous system damage underlying memory loss and Alzheimer’s disease, retinopathy and peripheral neuropathy, kidney diseases and shortened life-span [17,29,34,39,53,55]. Application of one time central leptin gene therapy to enhance leptin supply locally in the hypothalamus, although unconventional, offers an efficient and durable anti-diabetic treatment paradigm capable of preventing and mitigating both type 1 and 2 diabetes (Fig. 2). Furthermore, it is highly possible that the anti-obesity and anti-aging benefits of central leptin gene therapy demonstrated recently [10,11,35], are causally coupled to the potent anti-diabetic outcome of this therapy. In all, these preclinical indicators of health safety warrant further validation of the long-lasting anti-diabetic potential of central leptin therapy in sub-human primates and humans.

Acknowledgment

Supported by a grant from the National Institutes of Health (DK37273).

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

[1] Bagnasco M, Dube MG, Kalra PS, Kalra SP. Evidence for the existence of distinct central appetite and energy expenditure pathways and stimulation of ghrelin as revealed by hypothalamic site-specific leptin gene therapy. Endocrinology. 2002;143:4409–21. [PubMed]
[2] Bagnasco M, Dube MG, Katz A, Kalra PS, Kalra SP. Leptin expression in hypothalamic PVN reverses dietary obesity and hyperinsulinemia but stimulates ghrelin. Obesity Research. 2003;11:1463–70. [PubMed]
[3] Banks WA, DiPalma CR, Farrell CL. Impaired transport of leptin across the blood-brain barrier in obesity. Peptides. 1999;20:1341–5. [PubMed]
[4] Banks WA, Farr SA, Morley JE. The effects of high fat diets on the blood-brain barrier transport of leptin: failure or adaptation? Physiol Behav. 2006;88:244–8. [PubMed]
[5] Banks WA, Farrell CL. Impaired transport of leptin across the blood-brain barrier in obesity is acquired and reversible. Am J Physiol Endocrinol Metab. 2003;285:E10–5. [PubMed]
[6] Banting FG, Best CH. Pancreatic extracts. 1922. J Lab Clin Med. 1990;115:254–72. [PubMed]
[7] Bartness TJ, Kay Song C, Shi H, Bowers RR, Foster MT. Brain-adipose tissue cross talk. Proc Nutr Soc. 2005;64:53–64. [PubMed]
[8] Beretta E, Dube MG, Kalra PS, Kalra SP. Long-term suppression of weight gain, adiposity, and serum insulin by central leptin gene therapy in prepubertal rats: Effects on serum ghrelin and appetite-regulating genes. Ped. Res. 2002;52:189–98. [PubMed]
[9] Boghossian S, Dube MG, Torto R, Kalra PS, Kalra SP. Hypothalamic clamp on insulin release by leptin-transgene expression. Peptides. 2006;27:3245–54. [PubMed]
[10] Boghossian S, Lecklin AH, Torto R, Kalra PS, Kalra SP. Suppression of fat deposition for the life time of rodents with gene therapy. Peptides. 2005;26:1512–9. [PubMed]
[11] Boghossian S, Ueno N, Dube MG, Kalra P, Kalra S. Leptin gene transfer in the hypothalamus enhances longevity in adult monogenic mutant mice in the absence of circulating leptin. Neurobiol Aging. 2007;28:1594–604. [PubMed]
[12] Bray GA. Handbook of Obesity. Marcel Dekker; New York: 1998. Historical framework for the development of ideas about obesity; pp. 1–29.
[13] Briley LP, Szczech LA. Leptin and renal disease. Semin Dial. 2006;19:54–9. [PubMed]
[14] Buijs RM, Chun SJ, Niijima A, Romijn HJ, Nagai K. Parasympathetic and sympathetic control of the pancreas: a role for the suprachiasmatic nucleus and other hypothalamic centers that are involved in the regulation of food intake. J Comp Neurol. 2001;431:405–23. [PubMed]
[15] Burguera B, Couce ME, Curran GL, Jensen MD, Lloyd RV, Cleary MP, et al. Obesity is associated with a decreased leptin transport across the blood-brain barrier in rats. Diabetes. 2000;49:1219–23. [PubMed]
[16] Caro JF, Kolaczynski JW, Nyce MR, Ohannesian JP, Opentanova I, Goldman WH, et al. Decreased cerebrospinal-fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance. Lancet. 1996;348:159–61. [PubMed]
[17] Carr MC, Brunzell JD. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J Clin Endocrinol Metab. 2004;89:2601–7. [PubMed]
[18] Carter BJ, Burstein H. Adeno-associated virus and AAV vectors for gene delivery. In: Templeton-Smith N, editor. Theruapeutics mechanisms and strategies. Marcel Dekker; New York, NY: 2004. pp. 71–1011.
[19] Chinookoswong N, Wang JL, Shi ZQ. Leptin restores euglycemia and normalizes glucose turnover in insulindeficient diabetes in the rat. Diabetes. 1999;48:1487–92. [PubMed]
[20] Cohen P, Zhao C, Cai X, Montez JM, Rohani SC, Feinstein P, et al. Selective deletion of leptin receptor in neurons leads to obesity. J Clin Invest. 2001;108:1113–21. [PMC free article] [PubMed]
[21] Correia MLG, Rahmouni K. Role of leptin in the cardiovascular and endocrine complications of metabolic syndrome. Diabetes, Obesity, and Metabolism. 2006;8:603–10. [PubMed]
[22] Dhillon H, Ge Y, Minter RM, Prima V, Moldawer LL, Muzyczka N, et al. Long-term differential modulation of genes encoding orexigenic and anorexigenic peptides by leptin delivered by rAAV vector in ob/ob mice. Relationship with body weight change. Regul Pept. 2000;92:97–105. [PubMed]
[23] Dhillon H, Kalra SP, Kalra PS. Dose-dependent effects of central leptin gene therapy on genes that regulate body weight and appetite in the hypothalamus. Mol Ther. 2001;4:139–45. [PubMed]
[24] Dhillon H, Kalra SP, Prima V, Zolotukhin S, Scarpace PJ, Moldawer LL, et al. Central leptin gene therapy suppresses body weight gain, adiposity and serum insulin without affecting food consumption in normal rats: a long-term study. Regul Pept. 2001;99:69–77. [PubMed]
[25] Dube MG, Beretta E, Dhillon H, Ueno N, Kalra PS, Kalra SP. Central leptin gene therapy blocks high fat diet-induced weight gain, hyperleptinemia and hyperinsulinemia: effects on serum ghrelin levels. Diabetes. 2002;51:1729–36. [PubMed]
[26] Dube MG, Torto R, Kalra SP. Increased leptin expression selectively in the hypothalamus suppresses inflammatory markers CRP and IL-6 in leptin-deficient diabetic obese mice. Peptides. 2008;29:593–8. [PMC free article] [PubMed]
[27] Dube MG, Xu B, Kalra PS, Sninsky CA, Kalra SP. Disruption in neuropeptide Y and leptin signaling in obese ventromedial hypothalamic-lesioned rats. Brain Res. 1999;816:38–46. [PubMed]
[28] Ebihara K, Kusakabe T, Hirata M, Masuzaki H, Miyanaga F, Kobayashi N, et al. Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. J Clin Endocrinol Metab. 2007;92:532–41. [PubMed]
[29] Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab. 2004;89:2595–600. [PubMed]
[30] Hidaka S, Yoshimatsu H, Kondou S, Oka K, Tsuruta Y, Sakino H, et al. Hypoleptinemia, but not hypoinsulinemia, induces hyperphagia in streptozotocin-induced diabetic rats. J Neurochem. 2001;77:993–1000. [PubMed]
[31] Hidaka S, Yoshimatsu H, Kondou S, Tsuruta Y, Oka K, Noguchi H, et al. Chronic central leptin infusion restores hyperglycemia independent of food intake and insulin level in streptozotocin-induced diabetic rats. Faseb J. 2002;16:509–18. [PubMed]
[32] Iwaniec UT, Boghossian S, Lapke PD, Turner RT, Kalra SP. Central leptin gene therapy corrects skeletal abnormalities in leptin-deficient ob/ob mice. Peptides. 2007;28:1012–9. [PMC free article] [PubMed]
[33] Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444:840–6. [PubMed]
[34] Kalra PS, Kalra SP. Obesity and metabolic syndrome: long-term benefits of central leptin gene therapy. In: Prous JR, editor. Drugs of Today, Barcelona. Prous Science; Spain: 2002. pp. 745–57. [PubMed]
[35] Kalra SP. Central leptin insufficiency syndrome: An interactive etiology for obesity, metabolic and neural diseases and for designing new therapeutic interventions. Peptides. 2008;29:127–38. [PMC free article] [PubMed]
[36] Kalra SP. Circumventing leptin resistance for weight control. Proc Natl Acad Sci U S A. 2001;98:4279–81. [PubMed]
[37] Kalra SP. Disruption in the leptin--NPY link underlies the pandemic of diabetes and metabolic syndrome: New therapeutic approaches. Nutrition. 2008;24:820–6. [PMC free article] [PubMed]
[38] Kalra SP, Dube MG, Pu S, Xu B, Horvath TL, Kalra PS. Interacting appetiteregulating pathways in the hypothalamic regulation of body weight. Endocr Rev. 1999;20:68–100. [PubMed]
[39] Kalra SP, Kalra PS. Gene transfer technology: a preventive neurotherapy to curb obesity, ameliorate metabolic syndrome and extend life-expectancy. Trends Pharmacol Sci. 2005;26:488–95. [PubMed]
[40] Kalra SP, Kalra PS. NPY and cohorts in regulating appetite, obesity and metabolic syndrome: beneficial effects of gene therapy. Neuropeptides. 2004;38:201–11. [PubMed]
[41] Kamohara S, Burcelin R, Halaas JL, Friedman JM, Charron MJ. Acute stimulation of glucose metabolism in mice by leptin treatment. Nature. 1997;389:374–7. [PubMed]
[42] Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA, et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson’s disease: an open label, phase I trial. Lancet. 2007;369:2097–105. [PubMed]
[43] Kastin AJ, Pan W. Dynamic regulation of leptin entry into brain by the blood-brain barrier. Regul Pept. 2000;92:37–43. [PubMed]
[44] Kastin AJ, Pan W. Intranasal leptin: blood-brain barrier bypass (BBBB) for obesity? Endocrinology. 2006;147:2086–7. [PubMed]
[45] Kastin AJ, Pan W, Maness LM, Koletsky RJ, Ernsberger P. Decreased transport of leptin across the blood-brain barrier in rats lacking the short form of the leptin receptor. Peptides. 1999;20:1449–53. [PubMed]
[46] Keen-Rhinehart E, Kalra SP, Kalra PS. AAV mediated leptin receptor installation improves energy balance and the reproductive status of obese female Koletsky rats. Peptides. 2005;26:2567–78. [PubMed]
[47] Kieffer TJ, Habener JF. The adipoinsular axis: effects of leptin on pancreatic B-cells. Am. J. Physiol. Endocrinol. Metab. 2000;278:E1–E14. [PubMed]
[48] Kojima S, Akihiro A, Inui A, Kalra SP. Leptin as a substitute for insulin therapy in insulin-deficient diabetes-correction of hyperglycemia and hyperphagia and promotion of survival without diabetic complications; 90th Annual Meeting of The Endocrine Society; San Francisco. 2008.
[49] Kojima S, Asakawa A, Amitani H, Sakoguchi T, Ueno N, Inui A, et al. Central leptin gene therapy, a substitute for insulin therapy to ameliorate hyperglycemia and hyperphagia, and promote survival in insulin-deficient diabetic mice. Peptides. 2009;30:962–6. [PubMed]
[50] Koyama K, Shimabukuro M, Chen G, Wang MY, Lee Y, Kalra PS, et al. Resistance to adenovirally induced hyperleptinemia in rats. Comparison of ventromedial hypothalamic lesions and mutated leptin receptors. J Clin Invest. 1998;102:728–33. [PMC free article] [PubMed]
[51] Kreier F, Kap YS, Mettenleiter TC, van Heijningen C, van der Vliet J, Kalsbeek A, et al. Tracing from fat tissue, liver, and pancreas: a neuroanatomical framework for the role of the brain in type 2 diabetes. Endocrinology. 2006;147:1140–7. [PubMed]
[52] Kurrimbux D, Gaffen Z, Farrell CL, Martin D, Thomas SA. The involvement of the blood-brain and the blood-cerebrospinal fluid barriers in the distribution of leptin into and out of the rat brain. Neuroscience. 2004;123:527–36. [PubMed]
[53] Lazar MA. How obesity causes diabetes: not a tall tale. Science. 2005;307:373–5. [PubMed]
[54] Lecklin AH, Dube MG, Torto R, Kalra PS, Kalra SP. Perigestational suppression of weight gain with central leptin gene therapy results in lower weight F1 generation. Peptides. 2005;26:1176–87. [PubMed]
[55] Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev. 2002;23:201–29. [PubMed]
[56] Lin CY, Higginbotham DA, Judd RL, White BD. Central leptin increases insulin sensitivity in streptozotocin-induced diabetic rats. Am J Physiol Endocrinol Metab. 2002;282:E1084–E91. [PubMed]
[57] Lin EJ, Sainsbury A, Lee NJ, Boey D, Couzens M, Enriquez R, et al. Combined deletion of Y1, Y2, and Y4 receptors prevents hypothalamic neuropeptide Y overexpression-induced hyperinsulinemia despite persistence of hyperphagia and obesity. Endocrinology. 2006;147:5094–101. [PubMed]
[58] Lord G. Role of leptin in immunology. Nutr Rev. 2002;60:S35–8. S68–87. [PubMed]
[59] Luchsinger JA, Reitz C, Patel B, Tang MX, Manly JJ, Mayeux R. Relation of diabetes to mild cognitive impairment. Arch Neurol. 2007;64:570–5. [PubMed]
[60] Malhotra A, Vashistha H, Yadav VS, Dube MG, Kalra SP, Abdellatif M, et al. Inhibition of p66ShcA redox activity in cardiac muscle cells attenuates hyperglycemia-induced oxidative stress and apoptosis. Am J Physiol Heart Circ Physiol. 2009;296:H380–8. [PubMed]
[61] Minokoshi Y, Haque MS, Shimazu T. Microinjection of leptin into the ventromedial hypothalamus increases glucose uptake in peripheral tissues in rats. Diabetes. 1999;48:287–91. [PubMed]
[62] Miyanaga F, Ogawa Y, Ebihara K, Hidaka S, Tanaka T, Hayashi S, et al. Leptin as an adjunct of insulin therapy in insulin-deficient diabetes. Diabetologia. 2003;46:1329–37. [PubMed]
[63] Moller DE. New drug targets for type 2 diabetes and the metabolic syndrome. Nature. 2001;414:821–7. [PubMed]
[64] Murphy JE, Zhou S, Giese K, Williams LT, Escobedo JA, Dwarki VJ. Long-term correction of obesity and diabetes in genetically obese mice by a single intramuscular injection of recombinant adeno-associated virus encoding mouse leptin. Proc Natl Acad Sci U S A. 1997;94:13921–6. [PubMed]
[65] Muzzin P, Eisensmith RC, Copeland KC, Woo SL. Correction of obesity and diabetes in genetically obese mice by leptin gene therapy. Proc Natl Acad Sci U S A. 1996;93:14804–8. [PubMed]
[66] Ogawa Y, Masuzaki H, Hosoda K, Aizawa-Abe M, Suga J, Suda M, et al. Increased glucose metabolism and insulin sensitivity in transgenic skinny mice overexpressing leptin. Diabetes. 1999;48:1822–9. [PubMed]
[67] Olshansky SJ, Passaro DJ, Hershow RC, Layden J, Carnes BA, Brody J, et al. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med. 2005;352:1138–45. [PubMed]
[68] O’Rahilly S, Farooqi IS, Yeo GS, Challis BG. Minireview: human obesity-lessons from monogenic disorders. Endocrinology. 2003;144:3757–64. [PubMed]
[69] Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med. 2002;346:570–8. [PubMed]
[70] Otukonyong EE, Dube MG, Torto R, Kalra PS, Kalra SP. Central leptin differentially modulates ultradian secretory patterns of insulin, leptin and ghrelin independent of effects on food intake and body weight. Peptides. 2005;26:2559–66. [PubMed]
[71] Otukonyong EE, Dube MG, Torto R, Kalra PS, Kalra SP. High fat diet-induced ultradian leptin and insulin hypersecretion and ghrelin is absent in obesity-resistant rats. Obesity Research. 2005;I13:991–9. [PubMed]
[72] Owens DR, Zinman B, Bolli GB. Insulins today and beyond. Lancet. 2001;358:739–46. [PubMed]
[73] Pan W, Kastin AJ. Why study transport of peptides and proteins at the neurovascular interface. Brain Res Brain Res Rev. 2004;46:32–43. [PubMed]
[74] Petersen KF, Oral EA, Dufour S, Befroy D, Ariyan C, Yu C, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest. 2002;109:1345–50. [PMC free article] [PubMed]
[75] Pu S, Dube MG, Kalra SP, Kalra PS. Permanent interruption of information flow between hypothalamus and hindbrain produces obesity accompanied by a selective dark-phase hyperphagia and hyperinsulinemia. New Orleans, LA: 2003. W-33, Abs #831.7.
[76] Shi ZQ, Nelson A, Whitcomb L, Wang J, Cohen AM. Intracerebroventricular administration of leptin markedly enhances insulin sensitivity and systemic glucose utilization in conscious rats. Metabolism. 1998;47:1274–80. [PubMed]
[77] Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature. 1999;401:73–6. [PubMed]
[78] Sierra-Honigmann MR, Nath AK, Murakami C, Garcia-Cardena G, Papapetropoulos A, Sessa WC, et al. Biological action of leptin as an angiogenic factor. Science. 1998;281:1683–6. [PubMed]
[79] Slyper AH. The pediatric obesity epidemic: causes and controversies. J Clin Endocrinol Metab. 2004;89:2540–7. [PubMed]
[80] Stein CJ, Colditz GA. The epidemic of obesity. J Clin Endocrinol Metab. 2004;89:2522–5. [PubMed]
[81] Szanto I, Kahn CR. Selective interaction between leptin and insulin signaling pathways in a hepatic cell line. Proc Natl Acad Sci U S A. 2000;97:2355–60. [PubMed]
[82] Taubes G. Diabetes. Paradoxical effects of tightly controlled blood sugar. Science. 2008;322:365–7. [PubMed]
[83] Ueno N, Dube MG, Inui A, Kalra PS, Kalra SP. Leptin modulates orexigenic effects of ghrelin and attenuates adiponectin and insulin levels and selectively the dark-phase feeding as revealed by central leptin gene therapy. Endocrinology. 2004;145:4176–84. [PubMed]
[84] Ueno N, Inui A, Kalra SP, Kalra PS. Leptin transgene expression in the hypothalamus enforces euglycemia in diabetic, insulin-deficient nonobese Akita mice and leptin-deficient obese ob/ob mice. Peptides. 2006;27:2332–42. [PubMed]
[85] Unger RH. Longevity, lipotoxicity and leptin: the adipocyte defense against feasting and famine. Biochimie. 2005;87:57–64. [PubMed]
[86] Uyama N, Geerts A, Reynaert H. Neural connections between the hypothalamus and the liver. Anat Rec A Discov Mol Cell Evol Biol. 2004;280:808–20. [PubMed]
[87] Van Heek M, Compton DS, France CF, Tedesco RP, Fawzi AB, Graziano MP, et al. Diet-induced obese mice develop peripheral, but not central, resistance to leptin. J Clin Invest. 1997;99:385–90. [PMC free article] [PubMed]
[88] Wang J, Takeuchi T, Tanaka S, Kubo SK, Kayo T, Lu D, et al. A mutation in the insulin 2 gene induces diabetes with severe pancreatic beta-cell dysfunction in the Mody mouse. J Clin Invest. 1999;103:27–37. [PMC free article] [PubMed]
[89] Wang JL, Chinookoswong N, Scully S, Qi M, Shi ZQ. Differential effects of leptin in regulation of tissue glucose utilization in vivo. Endocrinology. 1999;140:2117–24. [PubMed]
[90] Wang ZW, Zhou YT, Kakuma T, Lee Y, Higa M, Kalra SP, et al. Comparing the hypothalamic and extrahypothalamic actions of endogenous hyperleptinemia. Proc Natl Acad Sci U S A. 1999;96:10373–8. [PubMed]
[91] Yoshioka M, Kayo T, Ikeda T, Koizumi A. A novel locus, Mody4, distal to D7Mit189 on chromosome 7 determines early-onset NIDDM in nonobese C57BL/6 (Akita) mutant mice. Diabetes. 1997;46:887–94. [PubMed]
[92] Yu X, Park BH, Wang MY, Wang ZV, Unger RH. Making insulin-deficient type 1 diabetic rodents thrive without insulin. Proc Natl Acad Sci U S A. 2008;105:14070–5. [PubMed]
[93] Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372:425–32. [PubMed]